Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
1970- GamB,    Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway
- NA, Lung, NCI-H441
TumCG↓, TumAuto↑, Beclin-1/ATG6↑, LC3‑Ⅱ/LC3‑Ⅰ↑, ROS↑, eff↓,
1971- GamB,    Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis
- in-vitro, Nor, MCF10 - in-vitro, BC, MDA-MB-435 - in-vitro, BC, MDA-MB-468 - in-vivo, NA, NA
Paraptosis↑, ER Stress↑, MMP↓, eff↓, selectivity↑, p‑ERK↑, p‑JNK↑, eff↓,
1972- GamB,  doxoR,    Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression
- in-vitro, BC, NA
eff↑, P-gp/ABCB1↓, ROS↑, survivin↓, p38↑,
1973- GamB,    Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain
- in-vitro, Liver, SMMC-7721 cell
Apoptosis↑, ROS↑, Trx↓, Trx1↓, Trx2↓, Mich↑,
2426- GamB,    Anti-cancer natural products isolated from chinese medicinal herbs
- Review, Var, NA
TfR1/CD71↓, MMP2↓, MMP9↓, ChemoSen↑,
7056- GamB,    Gambogic acid induces cell death via covalent binding with PRDX1 to regulate ER stress and autophagy
- in-vitro, RCC, 786-O
ER Stress↑, TumAuto↑, ROS↑, PrxI↓, Apoptosis↑, BID↑, p‑eIF2α↑, ATF4↑, CHOP/DDIT3↑,
7066- GamB,    Unravelling the Therapeutic Potential of Gambogic Acid: Deciphering Its Molecular Mechanism of Action and Emerging Role as an Anticancer Xanthone
- Review, Var, NA
angioG↓, TumMeta↓, ChemoSen↑, *cardioP↑, *Inflam↓, *AntiViral↑, *antiOx↑, NF-kB↓, TNF-α↓, COX2/PTGS2↓, iNOS↓, Apoptosis↑, TumAuto↑, TumCP↓, TumCI↓, BioAv↓, ROS↑, MMP↓, SIRT1↓, Akt↓, mTORC1↓, AMPK↑, LRIG1↑, ER Stress↑, Paraptosis↑, Ferroptosis↑, HSP90↓, GSH↓, lipid-P↑, GPx4↓, miR-21↓, PI3K↓, Akt↓, PTEN↑, ASAP2↓, CDK7↓,
7065- GamB,    Gambogic acid: A review of its pharmacological mechanisms against cancer
- Review, Var, NA
AntiTum↑, Apoptosis↑, TumCCA↑, angioG↓, Hif1a↓, VEGF↓, MMPs↓, TumMeta↓, NF-kB↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, P-gp/ABCB1↓, Shh↓, Pyro↑, Casp3↑, GSDME↑, ChemoSen↑, RadioS↑, BioAv↓, Bcl-2↓, Mcl-1↓, BAX↑, Half-Life↓, ROS↑, miR-21↓, MMP2↓, MMP9↓,
7064- GamB,    Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain
- in-vitro, GC, SGC-7901 - in-vitro, Liver, Bel-7402 - in-vitro, HCC, SMMC-7721 cell - in-vitro, Ovarian, HO-8910
TOP2↓, DNAdam↑, MDR1↓,
7063- GamB,    Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells
- vitro+vivo, Lung, H1299
TumCG↓, P53↑, MDM2↓, Apoptosis↑,
7062- GamB,  Chit,    Modified chitosan derivative micelle system for natural anti-tumor product gambogic acid delivery
- in-vivo, Nor, NA
*Half-Life↑, *toxicity↓,
7061- GamB,    An open-labeled, randomized, multicentered, phase IIa study for advanced cancer treatment by gambogic acid injection (THS)
- Trial, Var, NA
ORR↑, DCR↑, *toxicity↓,
7060- GamB,    New targets for the antitumor activity of gambogic acid in hematologic malignancies
- Review, Melanoma, RPMI-8226
AntiCan↑, TumCP↓, Apoptosis↑, SRC3↓, DIDO1/DIO-1↑, KCNH2/hERG↓, ROS↑, Bcl-2↓, P53↑, cMyc↓, VEGF↓, Casp3↑, cl‑PARP1↑, eff↓,
7059- GamB,    Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells
- in-vitro, CRC, HCT15
TumCP↓, Apoptosis↑, JNK↑, TumCCA↑, cycD1/CCND1↓, P53↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, MMP↓, Cyt‑c↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, XIAP↓, survivin↓,
7058- GamB,  docx,    Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells
- in-vitro, GC, BGC-823
ChemoSen↑, TumCCA↑, survivin↓,
7057- GamB,    Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system
- in-vitro, Var, NA
UPS↓,
7055- GamB,    Studies on the toxicity of gambogic acid in rats
- in-vivo, Nor, NA
toxicity↑,
7054- GamB,    An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors
- Trial, Var, NA
Dose↝, DCR↝,
7067- GamB,    Gambogic Acid and Its Role in Chronic Diseases
- Review, Var, NA
*NF-kB↓, PI3K↓, Akt↓, STAT3↓, STAT5↓, IL6↓, COX2/PTGS2↓, iNOS↓, MMPs↓, Src↓, PKA↓, CXCR4↑, VEGF↓, Bcl-2↓, Bcl-xL↓, IAP1↓, Mcl-1↓, survivin↓, cycD1/CCND1↓, HSP90↓, HSP70/HSPA5↓, MAPK↓, HATs↓, HDAC↓, FAK↓, ROS↑, MMP7↓, MMP9↓, α-tubulin↑, cl‑PARP↑, TNF-α↓, BID↑, BAD↑, Cyt‑c↑, Casp3↑, Casp9↑, *AntiArt↑, *antiPs↑,
7088- GAR,    Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer
- in-vitro, SCC, SCC4
TumCG↓, TumCP↓, Apoptosis↑, TumCCA↑, selectivity↑, NF-kB↓, COX2/PTGS2↓, VEGF↓,
7087- GAR,    Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential
- Review, Var, NA
HATs↓, p300↓, CBP↓, NF-kB↓, STAT3↓, PI3K↓, Akt↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, Inflam↓, angioG↓, TumCP↓, TumMeta↓, TumCCA↑, EMT↓, CSCs↓, P53↑, TrxR↓, ROS↑, JNK↑, DNAdam↑, mt-Apoptosis↑, ER Stress↑, CHOP/DDIT3↑, DDIT4↑, TRIB3↑, SESN2↑, miR-218↑, eff↑, ChemoSen↑, BioAv↓, Half-Life↓, BioAv↑,
7086- GAR,    Garcinol: An emerging epigenetic modifier with versatile anticancer properties
- Review, Var, NA
AntiCan↑, TumCG↓, TumMeta↓, toxicity↓, Apoptosis↑, angioG↓, *BioAv↝, HATs↓, p300↓, CBP↓, PI3K↓, Akt↓, NF-kB↓, STAT↓, mTOR↓, DFF45↓, survivin↓, N-cadherin↓, Twist↓, MMP2↓, MMP3↓, MMP9↓, Mcl-1↓, EZH2↓, NOTCH↓, CXCR4↓, PGE2↓, VEGF↓, mPGES-1↓, CycB/CCNB1↓, CDK2↓, CDK4/6↓, iNOS↓, COX2/PTGS2↓, IL1↓, TNF-α↓, PARP↑, Bcl-2↓,
7085- GAR,    Safety profile of 40% Garcinol from Garcinia indica in experimental rodents
- in-vivo, Nor, NA
*Dose↓, *toxicity↓,
7084- GAR,    A unique in vivo pharmacokinetic profile, in vitro metabolic stability and hepatic first-pass metabolism of garcinol, a promising novel anticancer phytoconstituent, by liquid chromatography–mass spectrometry
- in-vivo, Nor, NA
*BioAv↝, *Dose↝, *Inflam↓, *antiOx↑, *chemoPv↑, Wnt↓, β-catenin/ZEB1↓, ERK↓, PI3K↓, Akt↓, NF-kB↓, STAT3↓, TumCP↓, antiNeop↑, ChemoSen↑, chemoP↑,
7089- GAR,    Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling
- vitro+vivo, BC, MDA-MB-231 - in-vitro, Pca, DU145 - in-vitro, PC, NA
STAT3↓, TumCI↓, NF-kB↓, uPA↓, VEGF↓, MMP9↓,
7090- GAR,    Garcinol
AChE↓, BChE↓, *Inflam↓, *5LO↓, *PGE2↓, *antiOx↑, FAK↓, DNAdam↑, MMP↓, Casp↑, NF-kB↓, HATs↓, *toxicity↓,
7091- GAR,    Garcinol-A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug
- Review, Var, NA
antiOx↑, Inflam↓, HATs↓, p300↓, CBP↓, PCAF↓, cycD1/CCND1↓, STAT↓, PI3K↓, Akt↓, TumCP↓, TumCI↓, TumMeta↓, TumCCA↑, CDK2↓, CDK4↓,
7092- GAR,    Garcinol and Its Role in Chronic Diseases
- Review, Var, NA
antiOx↑, Inflam↓, AntiCan↑, NF-kB↓, STAT3↓, antiNeop↑, 5LO↓, eff↑, HATs↓, p300↓, PCAF↓, miR-200c↑, NOTCH1↓, CSCs↓, COX2/PTGS2↓, cycD1/CCND1↓, VEGF↓, PI3K↓, Akt↓, Wnt↑, β-catenin/ZEB1↓, ROS↑, CHOP/DDIT3↑, Bax:Bcl2↑, Casp8↑, FAK↓, *neuroP↑, PCNA↓, *GSTs↑,
7093- GAR,    Garcinol
- Review, AD, NA
*AChE↓, *BChE↓, *HATs↓, *Inflam↓, AntiCan↑,
7094- GAR,    A multi-targeted approach of garcinol for obesity intervention: Mechanistic insights and possible clinical applications
- Review, Nor, NA
*Obesity↓, *Appetite↓, *GutMicro↑, BioAv↝,
1636- GAR,    Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation
- Case Report, Obesity, NA
*Dose∅, *other↑,
1632- GAR,    Garcinia Cambogia, Either Alone or in Combination with Green Tea Causes Moderate to Severe Liver Injury
- Human, LiverDam, NA
HLA↑, other↑,
811- GAR,    Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells
- in-vitro, CRC, HT-29
mPGES-1↓, Hif1a↓, VEGF↓, CXCR4↓, MMP2↓, MMP9↓, Casp3↑, TumCP↓, PGE2↓,
810- GAR,  GEM,    Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures
- in-vitro, PC, NA
TumCP↓, Apoptosis↑, PARP↝, VEGF↝, MMPs↝, Casp↝, NF-kB↝, miR-21↝,
809- GAR,    High-Throughput Screen of Natural Product Libraries for Hsp90 Inhibitors
- Review, NA, NA
HRI↓, HSP90↓,
808- GAR,  CUR,    Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells
- in-vitro, PC, Bxpc-3 - in-vitro, PC, PANC1
tumCV↓, Apoptosis↑, Casp3↑, Casp9↑,
807- GAR,    Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells
- in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
TumCG↓, Apoptosis↑, TumCCA↑,
806- GAR,    Garcinol exerts anti-cancer effect in human cervical cancer cells through upregulation of T-cadherin
- vitro+vivo, Pca, HeLa - vitro+vivo, Cerv, SiHa
TumCI↓, TumCMig↓, TumCCA↑, Apoptosis↑, T-cadherin↑,
805- GAR,  Cisplatin,  PacT,    Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells
- Review, NA, NA
ERK↓, PI3K/Akt↓, Wnt/(β-catenin)↓, STAT3↓, NF-kB↓, ChemoSen↑, COX2/PTGS2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, VEGF↓, TGF-β↓, HATs↓, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↓, Let-7↑, MMP9↓, TumCCA↑, ROS↑, MMP↓, IL6↓, NOTCH1↓, antiNeop↑,
804- GAR,    Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest
- in-vitro, EC, HEC1B - in-vitro, EC, ISH
TumCP↓, TumCCA↑, P53↑, P21↑, CDK2↓, CDK4↓, cycD1/CCND1↓, CycB/CCNB1↓, p‑cJun↑,
803- GAR,    Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer
- in-vitro, Lung, H1299 - in-vitro, Lung, H460
TumCP↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↑, CDK6↑, P21↑, p27/CDKN1B↑, ERK↓, MAPK↓,
802- GAR,    Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway
- in-vitro, GC, HGC27
TumCP↓, TumCI↓, Apoptosis↑, PI3K/Akt↓, Akt↓, p‑mTOR↓, cycD1/CCND1↓, MMP2↓, MMP9↓, BAX↑, Bcl-2↓,
801- GAR,  Cisplatin,    Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers
- in-vivo, HNSCC, NA
Apoptosis↑, cycD1/CCND1↓, Bcl-2↓, survivin↓, VEGF↓, TumCG↓, Ki-67↓, CD31/PECAM-1↓,
800- GAR,    Garcinol Regulates EMT and Wnt Signaling Pathways In Vitro and In Vivo, Leading to Anticancer Activity against Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
EMT↓, MET↑, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↑, miR-200c↑, Let-7↑, p‑β-catenin/ZEB1↓, NF-kB↓,
799- GAR,    Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, NMSC, MCF10
TumCG↓, Apoptosis↑, NF-kB↓,
798- GAR,    Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol
- in-vitro, BC, MCF7
TumCP↓, TumCCA↑, Apoptosis↑, ac‑H3↑, ac‑H4∅, NF-kB↓, ac‑p65↑, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓,
812- GAR,    Anti-proliferative and anti-invasive effects of garcinol from Garcinia indica on gallbladder carcinoma cells
- in-vitro, Gall, GBC-SD - in-vitro, Gall, NOZ
TumCG↓, TumCI↓, MMP2↓, MMP9↓,
813- GAR,  GEM,    Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model
- in-vivo, PC, NA
TumCG↓, OS↑,
814- GAR,  PacT,    Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model
- in-vivo, BC, NA
Apoptosis↑, TumCCA↑, EMT↓, TumCI↓,
815- GAR,    Garcinol from Garcinia indica Downregulates Cancer Stem-like Cell Biomarker ALDH1A1 in Nonsmall Cell Lung Cancer A549 Cells through DDIT3 Activation
- vitro+vivo, Lung, A549
ALDH1A1↓, CHOP/DDIT3↑,

Showing Research Papers: 4101 to 4150 of 8269
Prev Page 83 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ASAP2↓, 1,   CDK7↓, 1,   DCR↑, 1,   DCR↝, 1,   DDIT4↑, 1,   DIDO1/DIO-1↑, 1,   KCNH2/hERG↓, 1,   LRIG1↑, 1,   ORR↑, 1,   SRC3↓, 1,   UPS↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 1,   lipid-P↑, 1,   Mich↑, 1,   PrxI↓, 1,   ROS↑, 11,   Trx↓, 1,   Trx1↓, 1,   Trx2↓, 1,   TrxR↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

TfR1/CD71↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 5,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↓, 1,   PI3K/Akt↓, 2,   SIRT1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 10,   Apoptosis↑, 18,   mt-Apoptosis↑, 1,   BAD↑, 1,   BAX↑, 3,   Bax:Bcl2↑, 1,   Bcl-2↓, 9,   Bcl-xL↓, 3,   BID↑, 2,   Casp↑, 1,   Casp↝, 1,   Casp3↑, 7,   Casp8↑, 2,   Casp9↑, 4,   CBP↓, 3,   Cyt‑c↑, 2,   Ferroptosis↑, 1,   GSDME↑, 1,   IAP1↓, 1,   iNOS↓, 3,   JNK↑, 2,   p‑JNK↑, 1,   MAPK↓, 4,   Mcl-1↓, 4,   MDM2↓, 1,   p27/CDKN1B↑, 1,   p38↑, 1,   Paraptosis↑, 2,   Pyro↑, 1,   survivin↓, 6,  

Transcription & Epigenetics(tgid=7) ⓘ

p‑cJun↑, 1,   EZH2↓, 1,   ac‑H3↑, 1,   ac‑H4∅, 1,   HATs↓, 7,   miR-21↓, 2,   miR-21↝, 1,   miR-218↑, 1,   other↑, 1,   PCAF↓, 2,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 4,   p‑eIF2α↑, 1,   ER Stress↑, 4,   HRI↓, 1,   HSP70/HSPA5↓, 1,   HSP90↓, 3,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   SESN2↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

DFF45↓, 1,   DNAdam↑, 3,   P53↑, 5,   PARP↑, 1,   PARP↝, 1,   cl‑PARP↑, 2,   cl‑PARP1↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 4,   CDK4↓, 3,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 9,   CycD3↓, 1,   cycE/CCNE↑, 1,   P21↑, 2,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH1A1↓, 1,   CSCs↓, 2,   EMT↓, 3,   ERK↓, 3,   p‑ERK↑, 1,   HDAC↓, 1,   Let-7↑, 2,   mTOR↓, 2,   p‑mTOR↓, 1,   mTORC1↓, 1,   NOTCH↓, 1,   NOTCH1↓, 2,   p300↓, 4,   PI3K↓, 8,   PTEN↑, 1,   Shh↓, 1,   Src↓, 1,   STAT↓, 2,   STAT3↓, 6,   STAT5↓, 1,   TOP2↓, 1,   TumCG↓, 9,   Wnt↓, 2,   Wnt↑, 1,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   CD31/PECAM-1↓, 1,   CDK4/6↓, 1,   E-cadherin↑, 2,   FAK↓, 3,   HLA↑, 1,   Ki-67↓, 1,   MET↑, 1,   miR-200c↑, 2,   MMP2↓, 6,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 9,   MMPs↓, 2,   MMPs↝, 1,   N-cadherin↓, 1,   PKA↓, 1,   T-cadherin↑, 1,   TGF-β↓, 1,   TRIB3↑, 1,   TumCI↓, 7,   TumCMig↓, 1,   TumCP↓, 13,   TumMeta↓, 5,   Twist↓, 1,   uPA↓, 1,   Vim↓, 2,   Zeb1↓, 2,   ZEB2↓, 1,   ZEB2↑, 1,   α-tubulin↑, 1,   β-catenin/ZEB1↓, 3,   p‑β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 4,   ATF4↑, 1,   Hif1a↓, 2,   VEGF↓, 10,   VEGF↝, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 6,   CXCR4↓, 2,   CXCR4↑, 1,   IL1↓, 1,   IL6↓, 2,   Inflam↓, 3,   mPGES-1↓, 2,   NF-kB↓, 13,   NF-kB↝, 1,   ac‑p65↑, 1,   PGE2↓, 2,   TNF-α↓, 3,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BChE↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 7,   Dose↝, 1,   eff↓, 4,   eff↑, 3,   Half-Life↓, 2,   MDR1↓, 1,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

EZH2↓, 1,   IL6↓, 2,   Ki-67↓, 1,   TRIB3↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 4,   antiNeop↑, 3,   AntiTum↑, 1,   chemoP↑, 1,   OS↑, 1,   toxicity↓, 1,   toxicity↑, 1,  
Total Targets: 198

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   GSTs↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

HATs↓, 1,   other↑, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 4,   NF-kB↓, 1,   PGE2↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BChE↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 2,   Dose↓, 1,   Dose↝, 1,   Dose∅, 1,   Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 1,  

Functional Outcomes(tgid=23) ⓘ

antiPs↑, 1,   Appetite↓, 1,   cardioP↑, 1,   chemoPv↑, 1,   neuroP↑, 1,   Obesity↓, 1,   toxicity↓, 4,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,  
Total Targets: 25

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page